| 词条 | Diridavumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = u | target = hemagglutinin | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1393659-46-5 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C=6400 | H=9934 | N=1702 | O=1996 | S=48 | molecular_weight = 144.2 kg/mol | synonyms = CR6261 }}Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2] This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 | journal = WHO Drug Information | volume = 28 | issue = 2 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for infectious disease and toxins}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association. 2 : Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。